Each program begins with a defined physiological question and a testable pharmacological hypothesis. Literature review and computational analysis are used to define and challenge that hypothesis and prioritize experimental work. Computational results are not experimental confirmation.
Evidence considered
Aeviant distinguishes published biology, preclinical evidence, company interpretation and program objectives. Computational analysis tests the internal consistency of a hypothesis and helps prioritize experimental work; it is never treated as experimental confirmation.
Advancement
A program can advance only when reproducible results support the intended pharmacology, chemistry is tractable and the available evidence justifies the next stage. Criteria are defined before results are interpreted wherever practicable.
Redirection or termination
Work may be redirected or stopped when the mechanism is not reproducible, differentiation is inadequate, chemistry or exposure becomes impractical, or safety evidence does not support continued development. Negative and contradictory results are part of the decision record.